KeijiTanimoto

Last Updated :2019/10/06

Affiliations, Positions
Research Institute for Radiation Biology and Medicine, ., Assistant Professor
E-mail
ktanimohiroshima-u.ac.jp
Self-introduction
Molecular Biology (Mechanisms of response to hypoxia or various stress stimuli, and transcriptional regulation of genes.)

Basic Information

Major Professional Backgrounds

  • 2007/04/01, Hiroshima University, Research Institute for Radiation Biology and Medicine
  • 2001/04/01, 2002/03/31, Hiroshima University, Research Institute for Radiation Biology and Medicine
  • 1996/04/01, 1997/09/30, Saitama Cancer Center, Research Institute
  • 2002/04/01, 2007/03/31, Hiroshima University, Research Institute for Radiation Biology and Medicine
  • 2000/01/01, 2001/03/31, Japan Society for the Promotion of Science, research fellow
  • 1998/07/01, 1999/12/31, Cell and Molecular Biology, Karolinska Institutet, guest researcher

Educational Backgrounds

  • Hiroshima University, Graduate School, Division of Dental Research, Japan, 1994/04, 1998/03
  • Hiroshima University, Faculty of Dentistry, Japan, 1988/04, 1994/03

Academic Degrees

  • Doctor of Philosophy in Dental Science, Hiroshima University

Educational Activity

  • 【Bachelor Degree Program】School of Medicine : Program of Medicine
  • 【Master's Program】Graduate School of Biomedical and Health Sciences : Division of Integrated Health Sciences : Program of Biomedical Science
  • 【Doctoral Program】Graduate School of Biomedical and Health Sciences : Division of Biomedical Sciences : Program of Radiation Biology and Medicine

Research Fields

  • Medicine,dentistry, and pharmacy;Basic medicine;General medical chemistry
  • Medicine,dentistry, and pharmacy;Dentistry;Surgical dentistry

Research Keywords

  • transcription
  • HIF-1
  • Transcription
  • hypoxia
  • individualized therapy
  • Pharmacogenetics

Affiliated Academic Societies

  • American Association for Cancer Research
  • The Japanese Pharmacological Society

Educational Activity

Course in Charge

  1. 2019, Undergraduate Education, Intensive, Practice for medical research
  2. 2019, Undergraduate Education, First Semester, Molecular Biology in Medicine
  3. 2019, Graduate Education (Master's Program) , First Semester, Molecular Biology and Radiological Science
  4. 2019, Graduate Education (Master's Program) , First Semester, Molecular Biology and Radiological Science

Research Activities

Academic Papers

  1. The Krüppel-like zinc finger transcription factor, GLI-similar 1, is regulated by hypoxia-inducible factors via non-canonical mechanisms., Biochemical and Biophysical Research Communications, 441(2), 499-506, 2013
  2. An association study between Hypoxia inducible Factor-1alpha (HIF-1) polymorphisms and osteonecrosis, PLOS ONE, 8(11), e79647, 2013
  3. Electrical stimulation accelerates neuromuscular junction formation through ADAM19/neuregulin/ErbB signaling in vitro, Neuroscience Letters, 545, 29-34, 2013
  4. Development of lymphoproliferative diseases by hypoxia-inducible factor-1a is associated with prolonged lymphocyte survival, PLOS ONE, 8(4), e57833, 2013
  5. Abnormal FHIT Transcripts in Human Breast Carcinomas: A Clinicopathological and Epidemiological Analysis of 61 Japanese Case., Cancer Research, 57, 1981-1985, 19970401
  6. Antitumor Effect of Carboplatin Conbined with Radiation on Tumors in Mice., Anticancer Research, 17, 2535-2538, 19970401
  7. Regulation of estragen receptar alpha gene mediated by prometer B responsible for its enhanced expression in human breast cancer, Nucleic Acids Research, 27(3), 903-909, 19990401
  8. Polymorphisms of the CYP1A1 and GSTM1 gene involved in oral squamous cell carcinoma in association with a cigarette dose., European Journal of Cancer= Oral Oncology, 35, 191-196, 19990401
  9. Abnormal FHIT transcripts found in both lung cancer and normal lung tissue., Genes= Chromosomes and Cancer, 24, 105-111, 19990401
  10. Cellular sensitivity determinants to docetaxel in human gastrointestinal cancers, International Journal of Oncology, 20(2), 333-338, 20010201
  11. Unique action determinants of double acting topoisomerase inhibitor, TAS-103, International Journal of Oncology, 19(5), 921-927, 20011101
  12. O6-methylguanine-DNA methyltransferase (MGMT) as a determinant of resistance to camptothecin derivatives, Japanese Journal of Cancer Research, 93(1), 93-102, 20020101
  13. Identification of Functional Hypoxia Response Elements in Promoter Region of the DEC1 and DEC2 Gene, Journal of Biological Chemistry, 277(49), 47014-47021, 20021201
  14. Bcl-2 in cancer and normal tissue cells as a prediction marker of response to 5-fluorouracil, International Journal of Oncology, 22(1), 181-186, 20030101
  15. Identification of Residues Critical for Regulation of Protein Stability and the Transactivation Function of the Hypoxia-Inducible Factor-1a by the von Hippel-Lindau Tumor Suppresor Gene Product, Journal of Biological Chemistry, 278, 6816-6823, 20030401
  16. Targeted gene delivery to human osteosarcoma cells with magnetic liposomes under a magnetic field, INTERNATIONAL JOURNAL OF ONCOLOGY, 22, 1065-1071, 20030401
  17. The expression and function of estrogen receptor a and b in human breast cancer and its clinical application., Endocrine- Related Cancer, 10, 193-202, 20030401
  18. Hypoxia-Inducible Factor-1a Polymorphisms Associated with Enhanced Transactivation Capacity, Implying Clinical Significance., Carcinogenesis, 24, 20030401
  19. High-flow arteriovenous malformation of the mandible: treatment and 7-year follow-up, British Journal of Oral and Maxillofacial Surgery, 41, 348-350, 20030401
  20. Personalized Medicine, and Our Recent Approaches, Annals of Cancer Research and Therapy, 11, 61-72, 20031001
  21. Mutation of the von Hippel-Lindau (VHL) gene in human colorectal carcinoma: Association with cytoplasmic accumulation of hypoxia-inducible factor (HIF)-1a, Cancer Science, 95, 149-153, 20040401
  22. Aberrant Methylation of Dihydropyrimidine Dehydrogenase Gene (DPYD) Promoter, DPYD Expression, and Cellular Sensitivity to 5-fluorouracil in Cancer Cells, Clinical Cancer Research, 10, 7100-7107, 20040401
  23. Repression of PML Nuclear Body-Associated Transcription by Oxidative Stress-Activated Bach2, Molecular and Cellular Biology, 24(8), 3473-3484, 20040401
  24. Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes, International Journal of Cancer, 111(4), 617-626, 20040901
  25. Single nucleotide polymorphism in the hypoxia-inducible factor-1alpha gene in colorectal carcinoma, Oncology Reports, 1033-1037, 20041101
  26. Differential gene expressions during immortalization of normal human fibroblasts and endothelial cells transfected with human telomerase reverse transcriptase gene., Int J Oncol, 24, 1435-1442, 20041201
  27. Activator Protein Accelerates Dihydropyrimidine Dehydrogenase Gene Transcription in Cancer Cells, Cancer Research, 65, 1055-1062, 20050401
  28. Differentially expressed genes throughout the cellular immortalization processes are quite different between normal human fibroblasts and endothelial cells, International Journal of Oncology, 87-95, 20050701
  29. Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers, Mol Cancer Ther, 5(3), 767-775, 20060301
  30. Chemosensitivity prediction in esophageal squamous cell carcinoma: Novel marker genes and efficacy-prediction formulae using their expression data, Int J Oncol, 28, 1153-1162, 20060501
  31. Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro, PHARMACOGENETICS AND GENOMICS, 17(1), 1-10, 2007
  32. Differential regulation of DEC2 among hypoxia-inducible genes in endometrial carcinomas, ONCOLOGY REPORTS, 17(4), 871-878, 2007
  33. EGFR activating aberration occurs independently of other genetic aberrations or telomerase activation in adenocarcinoma of the lung, ONCOLOGY REPORTS, 17(6), 1405-1411, 2007
  34. Hypoxia inducible factor-1 influences sensitivity to paclitaxel of human lung cancer cell lines under normoxic conditions, CANCER SCIENCE, 98(9), 1394-1401, 2007
  35. Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro, PHARMACOGENETICS AND GENOMICS, 17(1), 1-10, 2007
  36. EGFR activating aberration occurs independently of other genetic aberrations or telomerase activation in adenocarcinoma of the lung, Oncology Reports, 17, 1405-1411, 20070601
  37. Exploration of the genes responsible for unlimited proliferation of immortalized lung fibroblasts, EXPERIMENTAL LUNG RESEARCH, 34(7), 373-390, 2008
  38. Exploration of the genes responsible for unlimited proliferation of immortalized lung fibroblasts., Exp Lung Res, 34(7), 373-390, 20080901
  39. EMP3 as a tumor suppressor gene for esophageal squamous cell carcinoma., Cancer Letters, 274(2009), 25-32, 20090201
  40. EMP3 as a candidate tumor suppressor gene for solid tumors., Expert Opin. Ther. Targets., 13(7), 811-822, 20090701
  41. Activation of the hypoxia-inducible factor-1 in overloaded temporomandibular joint, and induction of osteoclastogenesis, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 393(4), 800-805, 2010
  42. Carcinogenesis and cellular immortalization without persistent inactivation of p16/Rb pathway in lung cancer, International Journal of Oncology, 36(5), 1217-1227, 20100501
  43. Basic helix-loop-helix transcription factor DEC1 negatively regulates CyclinD1, Journal of Pathology, 224(3), 420-429, 20110701
  44. HIF-1a polymorphisms associate with genetic aberrations in lung cancer, Respirology, 16(5), 796-802, 20110701
  45. Interactive effects of cell therapy and rehabilitation realize the full potential of neurogenesis in brain injury model, Neurosci Lett, 555(25), 73-78, 20131001
  46. Differential regulation of DEC2 among hypoxia-inducible genes in endometrial carcinomas, ONCOLOGY REPORTS, 17(4), 871-878, 200704
  47. The A Allele at rs13419896 of EPAS1 Is Associated with Enhanced Expression and Poor Prognosis for Non-Small Cell Lung Cancer, PLOS ONE, 10(8), 20150811
  48. Selection of a novel drug-response predictor in esophageal cancer: A novel screening method using microarray and identification of IFITM1 as a potent marker gene of CDDP response, INTERNATIONAL JOURNAL OF ONCOLOGY, 32(2), 413-423, 200802
  49. A Chemical Modulator of p53 Transactivation that Acts as a Radioprotective Agonist, MOLECULAR CANCER THERAPEUTICS, 17(2), 432-442, 201802
  50. Differentiated embryo chondrocyte plays a crucial role in DNA damage response via transcriptional regulation under hypoxic conditions, PLOS ONE, 13(2), 20180221
  51. Human carboxylesterase 1A2 expressed from carboxylesterase 1A1 and 1A2 genes is a potent predictor of CPT-11 cytotoxicity in vitro, PHARMACOGENETICS AND GENOMICS, 17(1), 1-10, 200701
  52. UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating effect on HIF-1 alpha, Nature Communications, 6, 201501
  53. Mitochondria are required for ATM activation by extranuclear oxidative stress in cultured human hepatoblastoma cell line Hep G2 cells, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 443(4), 1286-1290, 20140124
  54. Human mismatch repair gene, MLH1, is transcriptionally repressed by the hypoxia-inducible transcription factors, DEC1 and DEC2, ONCOGENE, 27(30), 4200-4209, 200807
  55. The transcribed-ultraconserved regions in prostate and gastric cancer: DNA hypermethylation and microRNA-associated regulation, ONCOGENE, 35(27), 3598-3606, 20160707
  56. EGFR activating aberration occurs independently of other genetic aberrations or telomerase activation in adenocarcinoma of the lung, ONCOLOGY REPORTS, 17(6), 1405-1411, JUN 2007
  57. Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers, MOLECULAR CANCER THERAPEUTICS, 5(3), 767-775, 200603
  58. Targeted gene delivery to human osteosarcoma cells with magnetic cationic liposomes under a magnetic field, INTERNATIONAL JOURNAL OF ONCOLOGY, 22(5), 1065-1071, 200305
  59. Chemosensitivity prediction in esophageal squamous cell carcinoma: Novel marker genes and efficacy-prediction formulae using their expression data, INTERNATIONAL JOURNAL OF ONCOLOGY, 28(5), 1153-1162, 200605
  60. OASIS modulates hypoxia pathway activity to regulate bone angiogenesis, SCIENTIFIC REPORTS, 5, 20151112
  61. Hypoxia-inducible factor-1 alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance, CARCINOGENESIS, 24(11), 1779-1783, 200311
  62. Single nucleotide polymorphism in the hypoxia-inducible factor-1 alpha gene in colorectal carcinoma, ONCOLOGY REPORTS, 12(5), 1033-1037, 200411
  63. Association of EPAS1 Gene rs4953354 Polymorphism with Susceptibility to Lung Adenocarcinoma in Female Japanese Non-Smokers, JOURNAL OF THORACIC ONCOLOGY, 9(11), 1709-1713, 201411
  64. Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells, CLINICAL CANCER RESEARCH, 10(20), 7100-7107, 20041015
  65. High-flow arteriovenous malformation of the mandible: treatment and 7-year follow-up, BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 41(5), 348-350, 200310
  66. IL-1 beta-mediated up-regulation of DEC1 in human gingiva cells via the Akt pathway, JOURNAL OF CELLULAR BIOCHEMISTRY, 113(10), 3246-3253, 201210
  67. Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes, INTERNATIONAL JOURNAL OF CANCER, 111(4), 617-626, 20040910
  68. Hypoxia inducible factor-1 influences sensitivity to paclitaxel of human lung cancer cell lines under normoxic conditions, CANCER SCIENCE, 98(9), 1394-1401, 200709
  69. Genetics of the hypoxia-inducible factors in human cancers, EXPERIMENTAL CELL RESEARCH, 356(2), 166-172, JUL 15 2017
  70. Simulated microgravity attenuates myogenic differentiation via epigenetic regulations, NPJ MICROGRAVITY, 4, 2018 May 23
  71. Simulated microgravity enhances CDDP-induced apoptosis signal via p53-independent mechanisms in cancer cells, PLOS ONE, 14(7), e0219363, 2019, Jul, 19